Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Clinical Cooperation Unit Dermato-Oncology

Prof. Dr. Jochen Sven Utikal

Primary malignant melanoma

The Clinical Cooperation Unit Dermato-Oncology is engaged in the diagnosis and therapy of skin tumors. Research results obtained are transferred directly into clinical practice. The main focus is on malignant melanoma, a tumor that originates from the pigment cells of the skin. The Clinical Cooperation Unit Dermato-Oncology conducts several translational research projects, including different Phase I-IV clinical trials, with innovative melanoma therapies. (LINK: clinical trials)

Translational research focuses on cellular plasticity of melanoma cells, target identification to overcome resistance mechanisms, immunosuppression in melanoma, and prognostic and predictive melanoma biomarker.


Prof. Dr. Jochen Sven Utikal
Dermato-Oncology (A370)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg
Tel: +49 621 383 4461

Selected Publications

  • Sahin U et al., (2020). An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 585(7823):107-112.
  • Bitsch R, et al. (2022). STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. J Immunother Cancer; 10(3):e004384.
  • Arkhypov I et al. (2022). HSP90? induces immunosuppressive myeloid cells in melanoma via TLR4 signaling. J Immunother Cancer, 10(9):e005551.
  • Steinfass T, et al. (2023). Secretogranin II influences the assembly and function of MHC class I in melanoma. Exp Hematol Oncol. 12:29.
to top
powered by webEdition CMS